Mostrar el registro sencillo del ítem
The incidence of post-transplant malignancies in kidney transplant recipients treated with Rituximab
dc.rights.license | open | en_US |
dc.contributor.author | BACHELET, T. | |
hal.structure.identifier | Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept] | |
dc.contributor.author | VISENTIN, Jonathan | |
dc.contributor.author | DAVIS, P. | |
dc.contributor.author | TATON, B. | |
dc.contributor.author | GUIDICELLI, G. | |
hal.structure.identifier | Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept] | |
dc.contributor.author | KAMINSKI, Hannah | |
hal.structure.identifier | Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept] | |
dc.contributor.author | MERVILLE, Pierre | |
hal.structure.identifier | Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept] | |
dc.contributor.author | COUZI, Lionel | |
dc.date.accessioned | 2022-11-15T09:06:37Z | |
dc.date.available | 2022-11-15T09:06:37Z | |
dc.date.issued | 2021-02 | |
dc.identifier.issn | 1399-0012 | en_US |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/170260 | |
dc.description.abstractEn | Background: Rituximab has been proposed as induction therapy in kidney transplant recipients (KTRs) with preformed donor-specific antibodies (DSA) or a positive flow cross-match. We here evaluated whether adding rituximab was associated with a higher incidence of post-transplant malignancies (PTM) due to greater immunosuppression. Patients and Methods: Forty-eight HLA-sensitized KTRs received induction therapy with anti-thymocyte globulin (ATG) and rituximab because of preformed DSA or a positive flow cross-match (RTX group). They were compared with a control group of 154 patients receiving ATG alone. Results: Thirty-nine of 202 (19.3%) patients developed PTM; the rate was similar in the RTX and no-RTX groups (14.6% vs. 20.8%, respectively, P=.3). The distributions of the types of cancer were similar between the two groups, with the majority being non-melanoma skin cancer (NMSC, n=24). The risk factors for PTM were male gender, age, history of cancer, and azathioprine. Conclusion: Our data do not indicate a higher rate of post-transplantation de novo malignancies after kidney transplantation in high-immunological risk patients who received induction therapy based on ATG and rituximab. | |
dc.language.iso | EN | en_US |
dc.subject.en | Alloantibodies | |
dc.subject.en | B-cell therapy | |
dc.subject.en | Malignancy | |
dc.subject.en | Rituximab | |
dc.title.en | The incidence of post-transplant malignancies in kidney transplant recipients treated with Rituximab | |
dc.type | Article de revue | en_US |
dc.identifier.doi | 10.1111/ctr.14171 | en_US |
dc.subject.hal | Sciences du Vivant [q-bio]/Immunologie | en_US |
dc.identifier.pubmed | 33247459 | en_US |
bordeaux.journal | Clinical Transplantation | en_US |
bordeaux.page | e14171 | en_US |
bordeaux.volume | 35 | en_US |
bordeaux.hal.laboratories | ImmunoConcEpT - UMR 5164 | en_US |
bordeaux.issue | 2 | en_US |
bordeaux.institution | Université de Bordeaux | en_US |
bordeaux.institution | CNRS | en_US |
bordeaux.peerReviewed | oui | en_US |
bordeaux.inpress | non | en_US |
hal.identifier | hal-03852645 | |
hal.version | 1 | |
hal.date.transferred | 2022-11-15T09:06:41Z | |
hal.export | true | |
dc.rights.cc | Pas de Licence CC | en_US |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical%20Transplantation&rft.date=2021-02&rft.volume=35&rft.issue=2&rft.spage=e14171&rft.epage=e14171&rft.eissn=1399-0012&rft.issn=1399-0012&rft.au=BACHELET,%20T.&VISENTIN,%20Jonathan&DAVIS,%20P.&TATON,%20B.&GUIDICELLI,%20G.&rft.genre=article |
Archivos en el ítem
Archivos | Tamaño | Formato | Ver |
---|---|---|---|
No hay archivos asociados a este ítem. |